Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Bajaj

Gastroenterology Burbank, IL Medical Doctor

NPI 1518943513 CMS profile 114526

4901 W 79Th St, Suite 1, Burbank, IL 60459

Open in the dashboard

General payments

$75,576

983 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajay Bajaj of Burbank, IL is reported in the CMS Open Payments database as having received $75,576 across 983 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,094 196
2024 General $9,158 159
2023 General $12,454 218
2022 General $7,904 162
2021 General $4,744 105
2020 General $4,559 31
2019 General $20,664 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Bajaj
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ajay Bajaj were reported at $16,094. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ajay Bajaj Gastroenterology median Middle half National median
2019 $20,664 $417 $126–$1,100 $163
2020 $4,559 $224 $74–$624 $114
2021 $4,744 $352 $106–$1,054 $132
2022 $7,904 $448 $129–$1,270 $149
2023 $12,454 $533 $150–$1,390 $160
2024 $9,158 $605 $160–$1,606 $164
2025 $16,094 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $27,218 170 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $12,075 219 payments
  3. Allergan Inc. $11,434 41 payments
  4. Madrigal Pharmaceuticals $3,938 23 payments
  5. RedHill Biopharma Inc. $3,657 41 payments
  6. Ardelyx, Inc. $1,752 21 payments
  7. Endogastric Solutions, Inc $1,748 17 payments
  8. Janssen Biotech, Inc. $1,286 59 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $1,087 66 payments
  10. Pinnacle Biologics, Inc $1,057 4 payments
  11. Other $10,324 322 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33,775 20 payments
  2. Food and Beverage $25,450 925 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,600 2 payments
  4. Consulting Fee $5,150 3 payments
  5. Travel and Lodging $3,620 26 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $950 1 payment
  7. Education $31 6 payments
Products named General payments · program years 2019–2025
  1. LINZESS $30,553 116 payments
  2. TRULANCE $8,699 19 payments
  3. REZDIFFRA $3,915 22 payments
  4. Talicia $3,641 39 payments
  5. XIFAXAN $1,899 149 payments
  6. IBSRELA $1,752 21 payments
  7. EsophyX $1,748 17 payments
  8. VIBERZI $1,539 25 payments
  9. RINVOQ $1,323 41 payments
  10. PLENVU $1,239 32 payments
  11. Other $17,545 676 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,102

Median for Gastroenterology: 569

Drug cost

$950,920

Median for Gastroenterology: $104,976

Branded share of claims

61.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 376 $333,217
Zeposia Ozanimod Hydrochloride Brand 13 $113,257
Rinvoq Upadacitinib Brand 12 $90,100
Dupixent Syringe Dupilumab Brand 12 $84,926
Xifaxan Rifaximin Brand 28 $63,540
Creon Lipase/Protease/Amylase Brand 23 $60,835
Trulance Plecanatide Brand 37 $44,091
Ibsrela Tenapanor Hcl Brand 22 $41,908
Zenpep Lipase/Protease/Amylase Brand 11 $39,078
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 350 $23,187

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$250,659

Medicare's payments for the services billed

Medicare patients

905

Average age 73

Services billed

2,301

515 women, 390 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 45%
Ischemic heart disease 39%
Chronic kidney disease 35%
Heart failure 28%
COPD 26%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LINZESS
$3,330 376 —
IBSRELA
$1,338 22 —
DUPIXENT
$485 12 —
CREON
$303 23 —
VOQUEZNA
$271 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

983 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record